NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
14/03/2023
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Snapshot rápido
COAVE THERAPEUTICS
ST13
US500000097197299Classe
Pedido
Registro
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Tipo de processo
Eventos registrados
Atualização mais recente
Classificação
Tipo de marca
Classes Nice
Data de depósito
Data de registro
Data de expiração
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
Última transação
Escritório responsável
Código da situação
Cadastro oficial
Fundamento do pedido
Código do desenho
Tipo de titular
Localização do titular
Examinador
Unidade examinadora
Localização atual
Titulares
Representantes
Pina Campagna CARTER, DELUCA AND FARRELL LLP
Classes Nice
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparations in the nature of viral systems, gene therapy systems, and nucleic acid delivery systems comprised of viral vectors, gene therapy vectors, nucleic acid delivery vectors, and cells used to deliver modified genetic material into other cells for medical purposes for the diagnosis, treatment or prevention of ophthalmological disorders, diseases of the central and peripheral nervous system, hereditary disorders, genetic disorders and disorders of monogenic origin; Pharmaceutical preparations and products in the nature of genetically modified cells for use in gene therapy for medical purposes; Pharmaceutical preparations, namely, vaccines, prophylactic pharmaceuticals in the nature of antigens, and other genetically modified pharmaceuticals cells or tissue for use in nucleic acid therapy, gene therapy and cell therapy; Drug delivery agents in the nature genetically modified compounds for medical, pharmaceutical or veterinary purposes; Biological tissue cultures for medical purposes; Chemical or biological reagents for medical, pharmaceutical or veterinary purposes, namely, for nucleic acid therapy, gene therapy and cell therapy; Biological preparations for medical, pharmaceutical or veterinary purposes, namely, for use in connection with medical and clinical gene therapy, nucleic acid therapy and cell therapy to diagnose, treat and prevent ophthalmological disorders, diseases of the central and peripheral nervous system, hereditary disorders, genetic disorders and disorders of monogenic origin
Classe 42
Product research and development in the fields of biotechnology, biology, biomedicine, pharmacy, medical sciences, gene therapy, chemistry and biochemistry; Biological, biomedical and pharmaceutical therapeutic research services; Research in the fields of pharmaceutical and biological therapeutic preparations, namely, gene therapy and nucleic acid delivery systems for use in clinical trials and post-marketing trials; Pharmaceutical research and development; Provision of scientific research information in the fields of pharmaceuticals, biomedicine, gene therapy, clinical trials and post-marketing trials; Biological research; Chemical analysis and research services; Providing medical and scientific research information in the field of clinical trials; conducting clinical trials for others; Medical research services
Histórico de despachos e eventos da marca no USPTO.
15 publicações encontradas
NOTICE OF REGISTRATION CONFIRMATION EMAILED
14/03/2023
REGISTERED-PRINCIPAL REGISTER
14/03/2023
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
27/12/2022
PUBLISHED FOR OPPOSITION
27/12/2022
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
07/12/2022
APPROVED FOR PUB - PRINCIPAL REGISTER
22/11/2022
TEAS/EMAIL CORRESPONDENCE ENTERED
21/11/2022
CORRESPONDENCE RECEIVED IN LAW OFFICE
21/11/2022
TEAS RESPONSE TO OFFICE ACTION RECEIVED
21/11/2022
NOTIFICATION OF NON-FINAL ACTION E-MAILED
04/10/2022
NON-FINAL ACTION E-MAILED
04/10/2022
NON-FINAL ACTION WRITTEN
04/10/2022
ASSIGNED TO EXAMINER
04/10/2022
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
05/01/2022
NEW APPLICATION ENTERED
03/01/2022
Proteção contínua da sua marca
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.